HRP20220811T1 - Agonistička sredstva za vezanje tnf receptora - Google Patents
Agonistička sredstva za vezanje tnf receptora Download PDFInfo
- Publication number
- HRP20220811T1 HRP20220811T1 HRP20220811TT HRP20220811T HRP20220811T1 HR P20220811 T1 HRP20220811 T1 HR P20220811T1 HR P20220811T T HRP20220811T T HR P20220811TT HR P20220811 T HRP20220811 T HR P20220811T HR P20220811 T1 HRP20220811 T1 HR P20220811T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
Links
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 title 1
- 230000001270 agonistic effect Effects 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (10)
1. Bispecifično antitijelo koje sadrži najmanje dvije vezne domene, pri čemu se prva vezna domena veže za prvi receptor superfamilije faktora nekroze tumora (TNF), i druga vezna domena se veže za drugi receptor superfamilije TNF,
gdje prva vezna domena koji se veže za CD40 sadrži
(a) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2323, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2324 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2325, i regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2326, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2327 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2328; ili
(b) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2321 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2322 i gdje
druga vezna domena koji se veže za 4-1BB (CD137) sadrži
(a) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2297, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2298 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2299, i
regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2300, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2301 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2302;
(b) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2241 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2242;
(c) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2255, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2256 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2257, i
regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2258, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2259 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2260;
(d) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2227 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2228;
(e) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2315, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2316 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2317, i regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2318, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2319 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2320; ili
(f) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2247 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2248.
2. Bispecifično antitijelo prema patentnom zahtjevu 1, koje je u formatu antitijela pune dužine.
3. Bispecifično antitijelo prema patentnim zahtjevima 1 ili 2, koje sadrži jednu ili više konstantnih domena teškog lanca imunoglobulina i/ili konstantnih domena lakog lanca imunoglobulina.
4. Molekula nukleinske kiseline koja kodira bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je, poželjno, molekula nukleinske kiseline sadržana u vektoru.
5. Stanica koja sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 4.
6. Farmaceutska kompozicija koja sadrži, kao aktivno sredstvo, bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, ili stanicu prema patentnom zahtjevu 5.
7. Farmaceutska kompozicija prema patentnom zahtjevu 6, koja dodatno sadrži farmaceutski prihvatljiv nosač i/ili ekscipijens.
8. Komplet koji sadrži bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, stanicu prema patentnom zahtjevu 5, ili farmaceutsku kompoziciju prema patentnom zahtjevu 6 ili 7.
9. Bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, stanica prema patentnom zahtjevu 5, ili farmaceutska kompozicija prema patentnom zahtjevu 6 ili 7 za uporabu kao lijek.
10. Bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, stanica prema patentnom zahtjevu 5, ili farmaceutska kompozicija prema patentnom zahtjevu 6 ili 7 za uporabu u liječenju bolesti odabrane iz grupe koja se sastoji od raka, infektivnih bolesti, upalnih bolesti, metaboličkih bolesti, autoimunih poremećaja i odbacivanja transplantata.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2015050255 | 2015-01-08 | ||
EP19194817.3A EP3623386B1 (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20220811T1 true HRP20220811T1 (hr) | 2022-09-30 |
Family
ID=55072677
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20220811TT HRP20220811T1 (hr) | 2015-01-08 | 2016-01-08 | Agonistička sredstva za vezanje tnf receptora |
HRP20191824TT HRP20191824T1 (hr) | 2015-01-08 | 2019-10-09 | Agonistička sredstva za vezivanje tnf receptora |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191824TT HRP20191824T1 (hr) | 2015-01-08 | 2019-10-09 | Agonistička sredstva za vezivanje tnf receptora |
Country Status (24)
Country | Link |
---|---|
US (3) | US10457735B2 (hr) |
EP (3) | EP3623386B1 (hr) |
JP (4) | JP6744326B2 (hr) |
KR (3) | KR102238326B1 (hr) |
CN (3) | CN111499752A (hr) |
AU (2) | AU2016205974B2 (hr) |
BR (1) | BR112017013189B1 (hr) |
CA (2) | CA2969888A1 (hr) |
CY (1) | CY1122399T1 (hr) |
DK (2) | DK3242890T3 (hr) |
ES (2) | ES2755527T3 (hr) |
HR (2) | HRP20220811T1 (hr) |
HU (2) | HUE048532T2 (hr) |
LT (1) | LT3623386T (hr) |
ME (1) | ME03576B (hr) |
MX (2) | MX2017008917A (hr) |
PL (2) | PL3242890T3 (hr) |
PT (2) | PT3242890T (hr) |
RS (2) | RS63384B1 (hr) |
RU (2) | RU2020115901A (hr) |
SG (2) | SG11201704597WA (hr) |
SI (2) | SI3242890T1 (hr) |
WO (1) | WO2016110584A1 (hr) |
ZA (1) | ZA201704797B (hr) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110981964B (zh) | 2013-01-14 | 2023-09-15 | Xencor股份有限公司 | 新型异二聚体蛋白 |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
KR102497443B1 (ko) | 2014-03-28 | 2023-02-08 | 젠코어 인코포레이티드 | Cd38 및 cd3에 결합하는 이중특이적 항체 |
CA2967426A1 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and tumor antigens |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
PE20171103A1 (es) | 2014-11-26 | 2017-08-07 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y cd38 |
KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
CN108699136B (zh) | 2015-12-07 | 2022-03-18 | Xencor股份有限公司 | 结合cd3和psma的异二聚抗体 |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
KR102426765B1 (ko) * | 2016-04-22 | 2022-07-29 | 엘리게이터 바이오사이언스 에이비 | Cd137에 대한 신규한 이중특이성 폴리펩타이드 |
RU2022104399A (ru) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | Биспецифические антитела-ингибиторы контрольных точек |
AU2017290086A1 (en) | 2016-06-28 | 2019-01-24 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
US11091557B2 (en) * | 2016-07-14 | 2021-08-17 | Genmab A/S | Methods of producing multispecific antibodies against CD40 and CD137 |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018045110A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CA3035343A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP7305538B2 (ja) | 2016-09-23 | 2023-07-10 | メルス ナムローゼ フェンノートシャップ | 細胞によって発現される生物活性を調節する結合分子 |
MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
IL268058B2 (en) | 2017-01-20 | 2023-09-01 | Magenta Therapeutics Inc | Compositions and methods for depleting cd137 plus cells |
CA3055433A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Humanized anti-cd40 antibodies |
WO2019016402A1 (en) | 2017-07-20 | 2019-01-24 | Aptevo Research And Development Llc | BINDING PROTEINS BINDING AT 5T4 AND 4-1BB, COMPOSITIONS AND METHODS RELATED THERETO |
SG11202000198QA (en) * | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
EP3676294A4 (en) * | 2017-08-28 | 2021-12-22 | Systimmune, Inc. | ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF |
AU2018348165A1 (en) | 2017-10-10 | 2020-05-21 | Gritstone Bio, Inc. | Neoantigen identification using hotspots |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗pd−1配列を用いた二重特異性および単一特異性抗体 |
KR20200090855A (ko) | 2017-11-22 | 2020-07-29 | 그릿스톤 온콜로지, 인코포레이티드 | 신생항원에 대한 접합 에피토프 제시 감소 |
JP2021506291A (ja) | 2017-12-19 | 2021-02-22 | ゼンコア インコーポレイテッド | 改変されたil−2 fc融合タンパク質 |
CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
EP3781599A1 (en) | 2018-04-18 | 2021-02-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
CN113454111A (zh) | 2018-11-06 | 2021-09-28 | 健玛保 | 抗体配制剂 |
US20220332800A1 (en) | 2018-11-20 | 2022-10-20 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
CA3132185A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
CA3137373A1 (en) | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
CA3169963A1 (en) | 2020-02-04 | 2021-08-12 | Genmab A/S | Antibodies for use in therapy |
WO2021202807A1 (en) * | 2020-03-31 | 2021-10-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Proteomic screening for lysosomal storage diseases |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
CN112175080B (zh) * | 2020-10-22 | 2021-05-25 | 优睿赛思(武汉)生物科技有限公司 | 抗人白介素-6高亲和力兔单克隆抗体及应用 |
IL303424A (en) | 2020-12-07 | 2023-08-01 | Genmab As | Combined treatment with antibodies and taxane |
CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
JP2024509915A (ja) * | 2021-03-09 | 2024-03-05 | ジェンマブ エー/エス | 治療におけるcd40およびcd137に対する多重特異性結合物質 |
KR20230154311A (ko) | 2021-03-10 | 2023-11-07 | 젠코어 인코포레이티드 | Cd3 및 gpc3에 결합하는 이종이량체 항체 |
AU2022255506A1 (en) | 2021-04-08 | 2023-11-09 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
BR112023027006A2 (pt) | 2021-06-21 | 2024-03-12 | BioNTech SE | Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação |
WO2024050318A1 (en) * | 2022-08-27 | 2024-03-07 | H. Lee Moffitt Cancer Center And Research Institute | Cd40l 41bbl bispecific proteins |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2467242A1 (en) * | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
CN101023102B (zh) * | 2004-09-17 | 2013-05-29 | 霍夫曼-拉罗奇有限公司 | 抗-ox40l抗体 |
WO2007109254A2 (en) * | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
PL2201100T3 (pl) * | 2007-09-14 | 2016-10-31 | Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu | |
PT2594590E (pt) * | 2007-12-14 | 2015-01-14 | Bristol Myers Squibb Co | Moléculas de ligação ao recetor humano ox40 |
US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
AU2011275749C1 (en) | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
CN103347898B (zh) | 2011-01-10 | 2017-12-05 | Ct大西洋有限公司 | 包括与肿瘤相关抗原结合抗体的联合治疗 |
AU2012299421B2 (en) * | 2011-08-23 | 2016-02-04 | Board Of Regents, The University Of Texas System | Anti-OX40 antibodies and methods of using the same |
GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
SG11201507781VA (en) * | 2013-03-18 | 2015-10-29 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
US11091557B2 (en) * | 2016-07-14 | 2021-08-17 | Genmab A/S | Methods of producing multispecific antibodies against CD40 and CD137 |
-
2016
- 2016-01-08 CA CA2969888A patent/CA2969888A1/en active Pending
- 2016-01-08 BR BR112017013189-7A patent/BR112017013189B1/pt active IP Right Grant
- 2016-01-08 RU RU2020115901A patent/RU2020115901A/ru unknown
- 2016-01-08 JP JP2017554647A patent/JP6744326B2/ja active Active
- 2016-01-08 CN CN201911288299.4A patent/CN111499752A/zh active Pending
- 2016-01-08 KR KR1020177021592A patent/KR102238326B1/ko active IP Right Grant
- 2016-01-08 ES ES16700136T patent/ES2755527T3/es active Active
- 2016-01-08 DK DK16700136.1T patent/DK3242890T3/da active
- 2016-01-08 PT PT167001361T patent/PT3242890T/pt unknown
- 2016-01-08 ES ES19194817T patent/ES2922398T3/es active Active
- 2016-01-08 RU RU2017127792A patent/RU2723131C2/ru active
- 2016-01-08 HU HUE16700136A patent/HUE048532T2/hu unknown
- 2016-01-08 SG SG11201704597WA patent/SG11201704597WA/en unknown
- 2016-01-08 PL PL16700136T patent/PL3242890T3/pl unknown
- 2016-01-08 PL PL19194817.3T patent/PL3623386T3/pl unknown
- 2016-01-08 CA CA3224830A patent/CA3224830A1/en active Pending
- 2016-01-08 CN CN201680005119.5A patent/CN109476761B/zh active Active
- 2016-01-08 AU AU2016205974A patent/AU2016205974B2/en active Active
- 2016-01-08 ME MEP-2019-278A patent/ME03576B/me unknown
- 2016-01-08 US US15/538,419 patent/US10457735B2/en active Active
- 2016-01-08 KR KR1020247005611A patent/KR20240028548A/ko active Search and Examination
- 2016-01-08 SG SG10202003171TA patent/SG10202003171TA/en unknown
- 2016-01-08 KR KR1020217009922A patent/KR102640769B1/ko active IP Right Grant
- 2016-01-08 SI SI201630421T patent/SI3242890T1/sl unknown
- 2016-01-08 DK DK19194817.3T patent/DK3623386T3/da active
- 2016-01-08 EP EP19194817.3A patent/EP3623386B1/en active Active
- 2016-01-08 RS RS20220653A patent/RS63384B1/sr unknown
- 2016-01-08 HU HUE19194817A patent/HUE059219T2/hu unknown
- 2016-01-08 WO PCT/EP2016/050308 patent/WO2016110584A1/en active Application Filing
- 2016-01-08 RS RS20191503A patent/RS59693B1/sr unknown
- 2016-01-08 EP EP16700136.1A patent/EP3242890B1/en active Active
- 2016-01-08 MX MX2017008917A patent/MX2017008917A/es active IP Right Grant
- 2016-01-08 PT PT191948173T patent/PT3623386T/pt unknown
- 2016-01-08 SI SI201631557T patent/SI3623386T1/sl unknown
- 2016-01-08 CN CN202311416068.3A patent/CN117843799A/zh active Pending
- 2016-01-08 EP EP22167212.4A patent/EP4071176A3/en active Pending
- 2016-01-08 HR HRP20220811TT patent/HRP20220811T1/hr unknown
- 2016-01-08 LT LTEP19194817.3T patent/LT3623386T/lt unknown
-
2017
- 2017-07-05 MX MX2020012240A patent/MX2020012240A/es unknown
- 2017-07-14 ZA ZA2017/04797A patent/ZA201704797B/en unknown
-
2019
- 2019-09-25 US US16/582,534 patent/US10927181B2/en active Active
- 2019-10-09 HR HRP20191824TT patent/HRP20191824T1/hr unknown
- 2019-11-13 CY CY20191101191T patent/CY1122399T1/el unknown
-
2020
- 2020-07-30 JP JP2020129222A patent/JP6950056B2/ja active Active
-
2021
- 2021-01-08 US US17/144,591 patent/US11814411B2/en active Active
- 2021-09-22 JP JP2021153986A patent/JP7390345B2/ja active Active
-
2022
- 2022-01-28 AU AU2022200571A patent/AU2022200571A1/en active Pending
-
2023
- 2023-04-04 JP JP2023060755A patent/JP2023085435A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
JP2022177090A5 (hr) | ||
HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
HRP20201503T1 (hr) | MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79 | |
HRP20201432T1 (hr) | Il-17a sredstvo za vezivanje i njegove uporabe | |
HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
HRP20200174T1 (hr) | Antitijela antigena 2 anti-krvne dendritične stanice i njihova uporaba | |
HRP20221041T1 (hr) | Anti-pd-1 antitijela i sastavi | |
JP2015535828A5 (hr) | ||
JP2013121353A5 (hr) | ||
HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
HRP20191277T1 (hr) | Anti-cd26 antitijela i njihove primjene | |
HRP20171775T1 (hr) | Molekule protutijela koje vežu trombin i njihova uporaba | |
RU2016100892A (ru) | Антитела против tweakr и их применение | |
JP2017113019A5 (hr) | ||
HRP20180776T1 (hr) | Antagonisti il17c za liječenje upalnih poremećaja | |
RU2016138744A (ru) | Антитела, фармацевтические композиции и их применения | |
HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
JP2016512214A5 (hr) | ||
RU2015102069A (ru) | Антитела к биотину и способы их применения | |
CO2018001256A2 (es) | Anticuerpos anti-cd154 y métodos para producir los mismos |